Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Usman Baber

Showing results (31-40 of 391) with videos related to

Pageof 40
Sort By:
The Medical Clinics of North America|March 28, 2024
Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long?Khawaja Hassan Akhtar, Usman Baber
JACC. Cardiovascular Interventions|September 20, 2020
Duration of Dual Antiplatelet Therapy After PCI: How Short Can We Go?Usman Baber, Dominick J Angiolillo
Journal of the American College of Cardiology|December 8, 2018
Left Main PCI With DES Versus CABG: Cautionary Note or Cause for Concern?Usman Baber, George D Dangas
Journal of the American College of Cardiology|August 29, 2015
The Shifting Pendulum for DAPT After PCI: Balancing Long-Term Risks for Bleeding and ThrombosisSamin K Sharma, Usman Baber
Circulation|November 6, 2012
Exercise physiology in the catheterization laboratory: still alive and well!Usman Baber, George D Dangas
Interventional Cardiology Clinics|September 14, 2020
The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial ExperienceZain Ul Abideen Asad, Usman Baber
JACC. Cardiovascular Interventions|November 25, 2017
Reply: Research and Therapeutic Nihilisms in Chronic Kidney DiseaseUsman Baber, Jaya Chandrasekhar, Roxana Mehran
JACC. Cardiovascular Interventions|August 24, 2019
Reply: DAPT Cessation and MACE in Elderly Patients: What Is the Optimal Regimen and Duration?Lauren Joyce, Usman Baber, Roxana Mehran
Nature Reviews. Cardiology|December 3, 2014
Balancing ischaemia and bleeding risks with novel oral anticoagulantsUsman Baber, Ioannis Mastoris, Roxana Mehran
US Cardiology|December 25, 2024
TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary InterventionJohny Nicolas, Usman Baber, Roxana Mehran
Pageof 40

Showing results (31-40 of 391) with videos related to

Sort By:
Pageof 40
The Medical Clinics of North America|March 28, 2024
Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long?Khawaja Hassan Akhtar, Usman Baber
JACC. Cardiovascular Interventions|September 20, 2020
Duration of Dual Antiplatelet Therapy After PCI: How Short Can We Go?Usman Baber, Dominick J Angiolillo
Journal of the American College of Cardiology|December 8, 2018
Left Main PCI With DES Versus CABG: Cautionary Note or Cause for Concern?Usman Baber, George D Dangas
Journal of the American College of Cardiology|August 29, 2015
The Shifting Pendulum for DAPT After PCI: Balancing Long-Term Risks for Bleeding and ThrombosisSamin K Sharma, Usman Baber
Circulation|November 6, 2012
Exercise physiology in the catheterization laboratory: still alive and well!Usman Baber, George D Dangas
Interventional Cardiology Clinics|September 14, 2020
The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial ExperienceZain Ul Abideen Asad, Usman Baber
JACC. Cardiovascular Interventions|November 25, 2017
Reply: Research and Therapeutic Nihilisms in Chronic Kidney DiseaseUsman Baber, Jaya Chandrasekhar, Roxana Mehran
JACC. Cardiovascular Interventions|August 24, 2019
Reply: DAPT Cessation and MACE in Elderly Patients: What Is the Optimal Regimen and Duration?Lauren Joyce, Usman Baber, Roxana Mehran
Nature Reviews. Cardiology|December 3, 2014
Balancing ischaemia and bleeding risks with novel oral anticoagulantsUsman Baber, Ioannis Mastoris, Roxana Mehran
US Cardiology|December 25, 2024
TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary InterventionJohny Nicolas, Usman Baber, Roxana Mehran
Pageof 40